Wealthfront Advisers’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-4,567
| Closed | -$843K | – | 937 |
|
|
2024
Q4 | $843K | Sell |
4,567
-3,613
| -44% | -$667K | ﹤0.01% | 696 |
|
|
2024
Q3 | $1.61M | Sell |
8,180
-621
| -7% | -$122K | 0.01% | 545 |
|
|
2024
Q2 | $1.82M | Sell |
8,801
-407
| -4% | -$84.1K | 0.01% | 509 |
|
|
2024
Q1 | $2.49M | Sell |
9,208
-252
| -3% | -$68.3K | 0.01% | 434 |
|
|
2023
Q4 | $2.24M | Buy |
9,460
+8,081
| +586% | +$1.91M | 0.01% | 436 |
|
|
2023
Q3 | $270K | Buy |
1,379
+205
| +17% | +$40.2K | ﹤0.01% | 774 |
|
|
2023
Q2 | $247K | Sell |
1,174
-629
| -35% | -$132K | ﹤0.01% | 792 |
|
|
2023
Q1 | $364K | Sell |
1,803
-331
| -16% | -$66.8K | ﹤0.01% | 721 |
|
|
2022
Q4 | $465K | Buy |
2,134
+285
| +15% | +$62.1K | ﹤0.01% | 644 |
|
|
2022
Q3 | $364K | Buy |
1,849
+464
| +34% | +$91.3K | ﹤0.01% | 660 |
|
|
2022
Q2 | $296K | Buy |
1,385
+333
| +32% | +$71.2K | ﹤0.01% | 687 |
|
|
2022
Q1 | $298K | Sell |
1,052
-4,157
| -80% | -$1.18M | ﹤0.01% | 707 |
|
|
2021
Q4 | $1.96M | Buy |
5,209
+2,085
| +67% | +$785K | 0.01% | 393 |
|
|
2021
Q3 | $1.29M | Buy |
3,124
+2,115
| +210% | +$873K | 0.01% | 434 |
|
|
2021
Q2 | $373K | Buy |
1,009
+162
| +19% | +$59.9K | ﹤0.01% | 554 |
|
|
2021
Q1 | $245K | Buy |
+847
| New | +$245K | ﹤0.01% | 523 |
|